argenx SE (EBR:ARGX)
685.80
+12.40 (1.84%)
At close: Jan 20, 2026
argenx SE Revenue
argenx SE had revenue of $1.15B USD in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.69B, up 93.18% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.52% growth.
Revenue (ttm)
$3.69B
Revenue Growth
+93.18%
P/S Ratio
13.37
Revenue / Employee
$2.31M
Employees
1,599
Market Cap
41.97B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.65% |
| Dec 31, 2012 | 4.00M | 11.07K | 0.28% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 5.64M |
| Onward Medical | 2.72M |
argenx SE News
- 21 hours ago - Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity - Seeking Alpha
- 6 days ago - Wedbush Reiterates Outperform Rating for ARGX with $1000 PT | ARGX Stock News - GuruFocus
- 7 days ago - Argenx (ARGX) Gains FDA Priority Review for Expanded Vyvgart Use - GuruFocus
- 7 days ago - Argenx bid for Vyvgart label expansion undergoes FDA priority review - Seeking Alpha
- 7 days ago - FDA Prioritizes Argenx's sBLA for Vyvgart in Myasthenia Gravis Treatment - GuruFocus
- 7 days ago - Argenx's VYVGART Moves Closer To Expanded MG Use As FDA Grants Priority Review - Nasdaq
- 7 days ago - argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - GlobeNewsWire
- 8 days ago - argenx SE at JPMorgan Healthcare Conference Transcript - GuruFocus